Dr. Ferran Morell Brotad talks about Pulmonary Fibrosis
Watch the video to learn a little bit more about Pulmonary Fibrosis, causes, symptoms and signs. Learn more about PF here: https://bit.ly/1lfMsiZ…
Dr. Ferran Morell Brotad talks about Pulmonary Fibrosis
Genentech Helps Pulmonary Fibrosis Foundation Programs
The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role…
Potential IPF Disease Biomarkers Seen in Patients’ Blood
Findings by a team of researchers suggest that levels of circulating endothelial cells and fibrocytes may be used as predictive biomarkers in idiopathic pulmonary fibrosis (IPF). The team’s study, “Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments,” was published in the journal…
Esbriet’s Promise and Potential as a PF Therapy
Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was the first drug to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…
Love Your Lungs – Living With Idiopathic Pulmonary Fibrosis
https://www.youtube.com/watch?v=CfmkE6zqT9A “Dolores has Idiopathic Pulmonary Fibrosis (IPF) and tells her story about living with lung disease. Dolores found help in dealing with her illness by contacting the Irish Lung Fibrosis Association (ILA).” Learn more about IPF: https://bit.ly/1XjPFMa…
Last Week’s Top-3 Most Read Posts On Pulmonary Fibrosis
1. Esbriet’s Promise and Potential as a PF Therapy 2. IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015 3. Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies …
PFF Brings Daughters of PF Program Under Its Wings
The Pulmonary Fibrosis Foundation (PFF) recently announced that it has acquired the Daughters of Pulmonary Fibrosis program from the Coalition for Pulmonary Fibrosis (CPF), a 501c(3) nonprofit organization based in California that serves the pulmonary fibrosis (PF) community. By assuming the administration of the Daughters of PF program and giving money raised…
Experimental IPF Therapies: Cotrimoxazole
Cotrimoxazole (Trisulfa-FPI) is a combination of trimethoprim and sulfamethoxazole in fixed amounts (trimethoprim 80 mg and sulfamethoxazole 400 mg) used to treat bacterial, fungal and protozoal infections. It is developed and marketed worldwide with different brand names including Septra (GlaxoSmithKline plc) and Bactrim (Hoffmann-La Roche). Being a broad…
New Anti-Fibrotic Drug Candidate MRG-201 Enters Phase 1 Clinical Trial
miRagen Therapeutics, Inc., a biopharmaceutical company dedicated to the development of pioneering therapies based on microRNAs, recently announced the start of a Phase 1 clinical trial on the company’s product MRG-201 developed as a therapy for fibrotic conditions. MicroRNAs (miRNAs) are small RNAs that act as master regulators of…
Pulmonary Fibrosis Foundation
“Patients, caregivers, and physicians discuss the disease and the role the Pulmonary Fibrosis Foundation has played in the past years.” Learn more about Pulmonary Fibrosis Foundation: https://bit.ly/1MkiSzf …
